+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Global Menopausal Hot Flashes Market: Untapped Lucrative Opportunities in Emerging Countries to Boost Demand for Menopausal Hot Flashes Therapies, says TMR

Posted on Oct 03, 2016

The global menopausal hot flashes market is moderately fragmented in nature with several small- and medium-sized players operating in the market, states a new market research study by Transparency Market Research (TMR). In 2014, the top eight companies held a collective share of 54.9% in the global menopausal hot flashes market, exhibiting a strong hold on the overall developments in the market. In the same year, Pfizer, Inc., Novartis International AG, and Novo Nordisk accounted for a 35.8% share in the global menopausal hot flashes market, thanks to the new product launches. The rising research and development activities and initiatives taken by the key players to create an awareness regarding therapeutics available in the market for menopausal hot flashes are expected to bolster the market across the world in the coming years, states a TMR analyst. 

As per the research report, the global market opportunity for menopausal hot flashes is expected to reach a value of US$5.26 bn by the end of 2023. On the basis of geography, North America is expected to lead the global market for menopausal hot flashes and account for a 61.7% share by the end of 2023. The growing healthcare awareness, increasing incidence of menopausal vasomotor symptoms, and approval of new drugs are some of the primary factors augmenting the growth of the menopausal hot flashes market in North America. 

Non-hormonal Menopausal Hot Flashes Therapy Segment to Gain Traction 

At present, the hormone-based therapy segment is leading the global menopausal hot flashes market, owing to the effective products used in the processes. This segment is expected to reach a value of US$4.88 bn by the end of 2023. Nevertheless, the rising concerns related to the side-effects of hormone replacement therapies (HRT) are expected to completely change the paradigm of the global menopausal hot flashes market. 

As a result, the demand for non-hormonal therapies is projected to witness a substantial rise in the coming years. “The rising number of cases of cardiovascular disorders and cancer in women across the globe linked with hormone therapies is anticipated to fuel the growth of the non-hormonal therapy segment in the near future,” says a TMR analyst.

Growing Awareness about Women’s Health to Bolster Global Menopausal Hot Flashes Market 

The growing incidence of menopausal vasomotor symptoms, including hot flashes has grown significantly in the last few years. This is one of the key aspects boosting the demand for menopausal hot flashes therapies in the global market. Additionally, the easy approval of new drugs and therapies for treating menopausal hot flashes is projected to encourage the growth of the global market, states a TMR analyst. Furthermore, the rising awareness regarding women’s health, especially in developing countries is expected to drive the demand throughout the forecast period. The introduction of combination therapies is also expected to contribute significantly towards the growth of the market.

Growing Demand for Alternative Therapies to Impede Growth of Global Market 

The rising risk of breast cancer associated with the treatment of hormone replacement therapy (HRT) is one of the key factors restricting the growth of the global menopausal hot flashes market. In addition, the rising demand for alternative therapies for hot flashes is expected to dampen the growth of the market throughout the forecast period. Nonetheless, the lucrative opportunities in developing nations will encourage the growth of the global menopausal hot flashes market in the next few years. 

This information is based on the findings of a report published by Transparency Market Research, titled “Menopausal Hot Flashes Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.” 

The global menopausal hot flashes market has been segmented as below: 

Therapy 

  • Hormonal Therapy
    • Estrogen
      • Premarin
      • Vivelle, Vivelle-Dot
    • Progesterone
      • Prometrium
  • Combination Product
    • Prempro
    • Duavee
  • Non-Hormonal Therapy
    • Brisdelle 

Pipeline Analysis 

  • Phase I and II Drugs
  • Phase III Drugs 

Geography 

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Rest of Europe
  • Asia Pacific
    • Australia
    • Japan
    • India
    • China
    • Rest of Asia Pacific
  • Rest of the World
    • Latin America
    • MENA 

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com 

Back To Top